NIKKEI 225
39,040.73 -28.95 (-0.07%) HANG SENG
19,233.25 -402.97 (-2.05%) CRUDE OIL
79.32 -0.48 (-0.60%) GOLD FUTURES
2,417.70 -20.80 (-0.85%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
55,787.54 +2,942.70 (+5.57%)
Genetic Technologies Limited (GENE)
After hours:
| Previous close | 2.3000 |
| Open | 2.3400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2100 - 2.3400 |
| 52-week range | 1.8000 - 5.9000 |
| Volume | |
| Avg. volume | 34,416 |
| Market cap | 10.63M |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees
MELBOURNE, Australia, May 06, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the execution of a strategic joint sales & marketing agreement with US based Wellworks for You Inc. (Wellworks). As part of the agreement, Wellworks will incorporate the geneType portfolio of tests into its fully flexible, scalable employee wellness solutions for orga
- GlobeNewswire
Appendix 4C & Quarterly Business Update – March 2024
Launching our most comprehensive test and expanding into new global marketsMELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 30 March 2024 (Q3 FY24). Key highlights: Cash Receipts totalling A$1.8m for the quarter ending March 2024.Launched tar
- GlobeNewswire
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Comp
